Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 7/20 | 0.46 |
| ▸ | PLD2 | O14939 | 5/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149522 | 0.90 | CCR5 (0.57) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL318445 | 0.87 | CCR5 (0.61) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL17140870 | 0.86 | CCR5 (0.62) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL318440 | 0.86 | CCR5 (0.62) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL318858 | 0.86 | CCR5 (0.75) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL17140762 | 0.83 | PKM (0.46) | CCR5PKMGPR119 | |
| SCHEMBL17141181 | 0.82 | ALDH1A1 (0.59) | CCR5OPRK1HTR2COPRM1AVPR1A | |
| SCHEMBL17140857 | 0.81 | NPC1L1 (0.50) | CCR5OPRK1OPRM1DRD3PKM | |
| SCHEMBL20340382 | 0.81 | SLC6A9 (0.50) | OPRM1PLD1PLD2SLC6A9 | |
| SCHEMBL17141234 | 0.80 | PKM (0.44) | CCR5PKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRK1 770/4885HTR2C 3773/4885 |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | CCR5 36/4885OPRK1 777/4885HTR2C 3826/4885 |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, CXCR3, SLC10A1 | CCR5 36/4885OPRK1 777/4885HTR2C 3826/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRK1 770/4885HTR2C 3773/4885 |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRK1 770/4885HTR2C 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.